Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing cutting-edge therapies for cancer treatment. With a promising pipeline that includes innovative agents utilizing immuno-oncology and epigenetic modulation, Syndax aims to address significant unmet medical needs across a range of malignancies. The company is committed to advancing its clinical programs, seeking to enhance patient outcomes and solidify its position as a pivotal player in the rapidly evolving cancer therapeutics market. Show more

Location: 730 THIRD AVENUE, NEW YORK, NY, UNITED STATES, 10017, 35 Gatehouse Dr Fl 3, New York, NY, 10017, USA | Website: https://syndax.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.765B

52 Wk Range

$8.58 - $22.73

Previous Close

$20.31

Open

$20.31

Volume

1,372,569

Day Range

$20.31 - $21.68

Enterprise Value

1.656B

Cash

116.8M

Avg Qtr Burn

-70.54M

Insider Ownership

1.28%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Revuforj® (revumenib) (SNDX-5613) Details R/R mNPM1 Acute Myeloid Leukemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Niktimvo (axatilimab-csfr) (SNDX-6352) Details Graft-versus-host disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revuforj® (Revumenib) Details Blood cancer, Cancer, Leukemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib + venetoclax + azacitidine Details Blood cancer, Cancer, Leukemia, Acute myeloid leukemia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Axatilimab (SNDX-6352) + Steroids Details Graft-versus-host disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Axatilimab (SNDX-6352) Details Idiopathic pulmonary fibrosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Axatilimab (SNDX-6352) + Jakafi® (ruxolitinib) Details Graft-versus-host disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib (SNDX-5613) Details Cancer, Metastatic colorectal cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib (SNDX-5613) + venetoclax + decitabine and cedazuridine Details Blood cancer, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib (SNDX-5613) + chemotherapy Details Blood cancer, Cancer, Leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib (SNDX-5613) w/ venetoclax and azacitidine Details Blood cancer, Cancer, Leukemia, Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib w/ 7+3 cytarabine + daunorubicin Details Blood cancer, Cancer, Leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Revumenib (SNDX-5613) Details Blood cancer, Cancer, Leukemia, Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.